New drug cocktail shows promise for Hard-to-Treat lymphoma
NCT ID NCT05025800
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 18 times
Summary
This study tests a new drug combination (ALX148, rituximab, and lenalidomide) in people with B-cell non-Hodgkin lymphoma that has not responded to prior treatment. The goal is to find the best dose and see if the combo can shrink or control the cancer. About 47 adults with various types of this lymphoma are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.